Mind Medicine Australia (MMA) is excited to announce a fund to support the development of observational trials into psychedelic-assisted therapies to treat a range of mental illnesses.
Who are the stakeholders behind the fund?
The initial commitment of funding of $1m will be provided by the Hunt Family Foundation with additional funding sought from other philanthropists. Applications will be managed by relevant members of the scientific and clinical advisory panel of Mind Medicine Australia chaired by Professor David Nutt, Head of Neuropsychopharmacology at Imperial College London.
The funding from the Hunt Family Foundation is the largest available philanthropic grant for this rapidly emerging field in Australia. Mind Medicine Australia (MMA) will also seek matched funding support from other philanthropists to leverage the impact of this initiative.
MMA advocated in 2021 for $15m to support mental health clinical trials utilising psychedelic-assisted therapies from the Federal Govt through the Medical Research Futures Fund.
Since then, Australia has seen a dramatic increase in the number of clinical trials cases involving psychedelic medicines. However, over the same period the mental health crisis in Australia has also worsened. There is now an urgent need to demonstrate that the high remission rates achieved in clinical trials to date can translate to more normalised clinical environments and to further improve the therapeutic methodology and protocols used.
What were the stakeholders’ thoughts on the grant?
Commenting on the new initiative by Mind Medicine Australia (MMA), the Chairman of MMA Peter Hunt said: “We are very hopeful that other philanthropists will join us because we urgently need to address the increasing mental health crisis in this country. The elephant in the room is the lack of innovation in treatments for mental illnesses for over 50 years.”
Professor Nutt said: “I am thrilled to Chair the review team that will oversee this venture. There is growing acceptance that observational trials collecting real world evidence are important in understanding the value and clinical utility of new treatments. They have proven vital to the development of medical cannabis and are likely to do the same for psychedelics.”
Tania de Jong, Executive Director of MMA, said: “Unlike conventional treatments, which often require patients to endure years of medications and weekly support from a professional, psychedelic-assisted therapies can be effective after just two to three clinically supervised sessions with the medicines supported by a short course of psychotherapy. The medicines have been shown to be safe when administered within a medically controlled environment.”
Who is eligible to apply for MMA’s initiative?
MMA welcomes applications for trials which focus on specific groups in the community – like, Veterans and First Responders – where patients often have multiple co-morbidities and are therefore harder to treat. Just last week Australia commemorated Vietnam Veteran’s Day.
Military veterans have the highest incidence of post-traumatic stress disorder (PTSD) and other mental illnesses in our community. More veterans die from suicide than on the battlefield. Many veterans with treatment resistant conditions could finally have the chance to heal through access to psychedelic-assisted therapies in medically controlled environments.
MMA is also interested in proposals which develop different therapeutic approaches, including tools to support patients. All applications will be processed on merit and the allocation of funds will be based on recommendations from the panel of scientific experts. Applications must contain a detailed timeline for the proposed trial, an estimated budget, sources of co-funding (if available) and details of how the trial will be supported, amongst other criteria.
Successful grants will be subject to the applicants receiving approval from an ethics committee for the proposed observational trial. Mind Medicine Australia will be setting out detailed application criteria on its website shortly. As part of the process, we welcome an active and open dialogue with researchers to maximise the impact of this initiative.
